Sakura Star Study – Chugai Pharmaceuticals NMO Clinical Trial

Post Reply
HSowalla
Forum Admin
Forum Admin
Posts: 25
Joined: Sat Sep 02, 2017 11:24 pm

Sakura Star Study – Chugai Pharmaceuticals NMO Clinical Trial

Post by HSowalla » Tue Sep 05, 2017 1:58 pm

Sakura Star Study – Chugai Pharmaceuticals NMO Clinical Trial

One of those medicines, we call SA237, is a monoclonal antibody against an IL-6 receptor. And I will talk actually a bit more about IL-6 later. This molecule is in a clinical study we call Sakura Star study or the code of the study is SA309-JG.

The objective of this study is to evaluate the efficacy, safety, pharmacodynamic, pharmacokinetic and immunogenic profiles of SA237 in patients with NMO and NMOSD.


Ages Eligible for Study:
- 12 Years to 74 Years (Child, Adult, Senior)
Sexes Eligible for Study:
- All
Accepts Healthy Volunteers:
- No

Criteria:

Inclusion Criteria:
- NMO or NMOSD
- Age 12 to 74 years, inclusive at the time of informed consent.

Exclusion Criteria
- Pregnancy or lactation.
- Evidence of other demyelinating disease or progressive multifocal leukoencephalopathy (PML).
- Known active infection (excluding fungal infections of nail beds or caries dentium) within 4 weeks prior to baseline.



For more information please visit: https://clinicaltrials.gov/ct2/show/NCT02028884
Heather Sowalla

"Hope is being able to see that there is light despite all of the darkness."

+NMO AQP4
Preventative Treatment: Imuran (250mg) + Rituxan (2 Full Doses Every 3 Months)

Admin Teen & YA Support Group

Post Reply

Return to “Clinical Research”